Test Code DGXN Digoxin Level
Additional Codes
Cerner |
NextGen |
Digoxin Level |
Digoxin Level |
Alternate Name(s)
Lanoxin
Digitek
Methodology
Enzymatic Heterogenous CIA, Multiple-point immuno-rate
Patient Preparation
- Specimens should be drawn at least 6 – 8 hours, preferably 12-24 hours, after the last dose.
- If toxicity is suspected, specimens may be drawn at any time.
Collection Instructions
Standard phlebotomy practices.
Specimen Requirements
Container |
|
||||||||||||
Stability |
|
||||||||||||
Rejection Criteria |
Gross Hemolysis |
Result Reporting and Reference Values
Reported as ng/mL.
|
Low |
High |
Critical Low |
Critical High |
Therapeutic Range |
0.8 |
2.0 |
N/A |
2.5 |
Reflex Testing
None
Limitations
- Ortho reports the following biases:
- Gentisic Acid at 5.0 mg/dL can cause a +0.45 ng/mL bias
- N-acetylcsteine at 90.0 mg/dL can cause a +1.11 ng/mL bias
- Bilirubin at 20 mg/dL can cause a +0.54 ng/mL bias
- Hemoglobin at 300 mg/dL can cause a -0.56 ng/mL bias
- Digoxin Immune FAB (Digibind) can interfere with immunoassay measurements
- Ortho reports no significant effect with the following:
- Lipemia up to 800 mg/dL
- The following interpretive data is visible to the practitioner:
- Digibind therapy yields invalid digoxin results. Gentisic Acid, a total bilirubin > 20 mg/dl and N-acetylcysteine create significant positive bias.
Useful For
Digoxin is a widely prescribed cardiac glycoside indicated in the treatment of congestive heart failure and supraventricular arrhythmias. Digoxin measurements are used to monitor patient compliance and therapy, and to diagnose potential overdose.